Review Article

The Role of Adenosine $A_{2A}$ Receptor, CYP450s, and PPARs in the Regulation of Vascular Tone

Maan T. Khayat$^{1,2}$ and Mohammed A. Nayeem$^1$

$^1$Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA
$^2$Department of Pharmaceutical Chemistry, School of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence should be addressed to Mohammed A. Nayeem; mnayeem@hsc.wvu.edu

Received 19 April 2017; Revised 22 June 2017; Accepted 12 July 2017; Published 13 August 2017

Academic Editor: Hugo Gutiérrez-De-Terán

Copyright © 2017 Maan T. Khayat and Mohammed A. Nayeem. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adenosine is an endogenous mediator involved in a myriad of physiologic functions, including vascular tone regulation. It is also implicated in some pathologic conditions. Four distinct receptor subtypes mediate the effects of adenosine, such as its role in the regulation of the vascular tone. Vascular tone regulation is a complex and continuous process which involves many mechanisms and mediators that are not fully disclosed. The vascular endothelium plays a pivotal role in regulating blood flow to and from all body organs. Also, the vascular endothelium is not merely a physical barrier; it is a complex tissue with numerous functions. Among adenosine receptors, $A_{2A}$ receptor subtype ($A_{2A}$AR) stands out as the primary receptor responsible for the vasodilatory effects of adenosine. This review focuses on important effectors of the vascular endothelium, including adenosine, adenosine receptors, EETs (epoxyeicosatrienoic acids), HETEs (hydroxyeicosatetraenoic acids), PPARs (peroxisome proliferator-activated receptors), and $K_{ATP}$ channels. Given the impact of vascular tone regulation in cardiovascular physiology and pathophysiology, better understanding of the mechanisms affecting it could have a significant potential for developing therapeutic agents for cardiovascular diseases.

1. Introduction

The vascular system of the human is known to be the major pathway for nutrition exchange among cells as well as organs (i.e., it connects the heart with organs and other tissues) [1]. Likewise, the blood vessels are the tree branches: they originate from the heart through the aorta and conduit arteries to fine capillaries. Blood runs in vessels by proper pressure, and therefore any change or deregulation of blood pressure will result in serious diseases [2]. For example, if blood pressure is low as in hypotension, it could result in organ failure (e.g., acute renal failure) [3]. On the other hand, if blood pressure is high as in hypertension, which is one of the main risk factors for cardiovascular disease, it results in serious diseases such as stroke and chronic renal failure [4]. Currently, hypertension affects over 25% of the human adult population globally [5]. Therefore, it is very important to have optimum blood pressure. Over the past decade, research has been focusing on investigating vascular tone regulation.

Physiologically, vascular tone is the contractile tension of a blood vessel relative to its maximum dilation. Vascular tone regulation is one of the complicated mechanisms in the human body. It involves multiple physiological mechanisms and mediators such as the atrial natriuretic peptide, eicosanoids, adrenal steroids, sodium and water excretion, neurologic control, kallikrein-kinin, and renomedullary endothelial systems [6]. The vascular wall is composed of three layers: intima, media, and adventitia [7]. In the intima layer, the vascular endothelium lines all vessels. The best description of the endothelium could be the printed circuit board (PCB), which is composed of wires, capacitors, and resistors that deliver a particular order by the programmer (i.e., it contains all necessary information for specific functions). Likewise, the vascular endothelium contains all important proteins, enzymes, and ion channels that serve in vascular tone regulation. However, the signaling pathways and their involvement in vascular tone are still not fully clear. The aim of this review is to summarize the previous work...
of our lab for the past twelve years as well as touch on the related work from other laboratories in relation to vascular tone regulation. In particular, we will address the role of the endothelium, cytochrome P450s (CYPs), and peroxisome proliferator-activated receptors (PPARs) in vascular tone regulation employing disease models, genetic manipulation, and pharmacologic intervention.

2. The Role of the Endothelium in Vascular Tone Regulation

For a long time, the endothelium was considered an inert cellophane-like membrane, which coated the entire vascular tree, and its primary function was thought to only regulate the blood vessel wall permeability [8] or to be a mechanical barrier [6]. With the advancement of technology and research, the endothelium is currently viewed as a dynamic, heterogeneous, widely spread tissue that has numerous functions involving secretion, synthesis, metabolism, and immunology [8]. In a human adult, the endothelium consists of between 1 and 6 $\times$ 10$^{13}$ cells, weighs about 1 kg, and covers a surface area of 3 m$^2$. Also, the endothelium makes up the innermost layer, intima, of all vessels but has different structures and composition based on vessel type [9]. Considering the previous facts and figures, the endothelium is described by some as the largest organ [10, 11]. Since it is a disseminated tissue, it interacts with many systems and has an intricate role in “end organ disease of systems,” which include neurologic, renal, hepatic, cardiac, dermatologic, immunologic, and vascular systems [12].

The role of the endothelium in the vasculature is not only merely to serve as a barrier between the circulation and surrounding tissue; it has a critical function in vascular tone regulation by producing some chemical substances (mediators) that affect vascular hemodynamics. These mediators can be divided into two types: (1) vasodilators, such as endothelium-derived relaxing factors (EDRFs), nitric oxide (NO), prostacyclin (PGI$_2$) [8], and endothelium-derived hyperpolarizing factors (EDHF) [13–16], and (2) vasoconstrictors, which include endothelin-1, reactive oxygen species (ROS), platelet-activating factor (PAF) [8], and arachidonic acid (AA) cyclooxygenase-derived metabolites [17].

It is important to understand the functional complexity of the vascular endothelium; any chronic or acute disruption can cause endothelial dysfunction. This explains its involvement in many diseases such as cardiovascular disease, insulin resistance, obesity, and type 2 diabetes [18, 19]. A clear indicator of endothelial dysfunction is disabling the bioavailability of NO. Moreover, one or more of the following characteristics accompany endothelial dysfunction: reduction of endothelium-mediated vasorelaxation, enhanced cell layer permeability, increased production of reactive oxygen species (ROS), excessive oxidative stress, and overexpression of inflammatory genes [20–24].

The vascular endothelium plays a major role in mediating vascular tone. The cellular level, function, and pathogenesis of the vascular endothelium were explored deeply [8, 19, 25–28]; however, the exact signaling mechanism, enzymes, and substrates involved are not totally revealed. Therefore, we summarized the mechanisms and signaling pathways within the endothelium based on the work done at our lab and by others.

3. The Role of $A_{2A}$ Adenosine Receptor in Vascular Tone Regulation

Adenosine receptors are involved in many signaling pathways and downstream effects [14, 15, 29–35]. For instance, they modulate and maintain many mechanisms such as cell growth, apoptosis, cell proliferation, angiogenesis, and immune response in addition to their involvement in diseases like asthma, Parkinson’s disease, hypertension, and cancer [29, 36–38]. Moreover, adenosine receptors such as $A_{2A}$ have significant effects in neurodegenerative diseases such as Alzheimer’s disease [39], schizophrenia [40], and Huntington’s disease [41]. However, $A_1$AR is implicated in pathological diseases such as Parkinson’s disease and Alzheimer’s disease [42]. Therefore, it is worthy to discuss the insightful mechanisms of adenosine and its receptors specifically in vascular tone regulation. The scope of this part is to discuss $A_{2A}$AR and $A_1$AR in relation to CYPs, high salt, low salt, and soluble epoxide hydrolase (sEH) in vascular tone regulation. Both receptors belong to the G protein coupled receptors (GPCRs) family [43]. $A_1$AR and $A_2$AR bind to $G_4$ proteins family, whereas $A_{2A}$AR and $A_{3A}$AR bind with $G_4$ protein. The distribution of $A_{3A}$AR and $A_1$AR is not the same in the body [43, 44]. For instance, $A_{3A}$AR is highly distributed in the spleen, thymus, leukocytes, blood platelets, heart, lung, blood vessels, and brain [43]. Particularly in the brain, $A_{2A}$AR is highly expressed in the hippocampus [45], which is involved in Alzheimer’s disease [46]. In addition, $A_{2A}$AR is present in astrocytes, oligodendrocytes, microglia, and neurons [47, 48]. It is also reported that $A_{2A}$AR is present in dendritic spines and postsynaptic regions of the basal ganglia [49]. However, with the high $A_{2A}$AR expression in the brain, it has limited expression (“restrictive localization”) in the striatum and olfactory bulb [50]. Moreover, $A_{2A}$AR has various actions such as mediating vasodilation and aiding in new blood vessels build-up [51]. On the other hand, $A_1$AR is highly expressed in the CNS on neurons of the cortex, hippocampus, and cerebellum in the brain [50]. Adenosine $A_1$ receptor also exists in microglia [52], astrocytes [53], and oligodendrocytes [54]. In addition, $A_1$AR is found in other parts of the body such as adipose tissue, heart, and kidneys [44]. In the vascular system, $A_1$AR mediates the vasoconstrictive effect of adenosine in vascular beds [55, 56].

GPCRs, including $A_1$AR and $A_{3A}$AR, are known to form homo-, multi-, and heterodimers [57]. For example, if the same GPCRs bind together, they form a homodimer, whereas if different receptors bind together, they form a heterodimer [58]. If part of the heteromeric complex is activated, it will manipulate the receptor binding properties of the same complex [59]. Similarly, adenosine receptors are reported to form homodimers among each other and heterodimers with other GPCRs [58]. A good example of homodimer formation in ARs is $A_1$AR which has been reported in the intact tissue of the cortex in different species [60] and in Purkinje cells of the
| Class                        | Reagents                     | Reagents' full description                                                                 |
|-----------------------------|------------------------------|------------------------------------------------------------------------------------------|
| Nonspecific AR agonist      | NECA                         | 5′-N-Ethylcarboxamidoadenosine                                                            |
| Specific A₂A AR agonist     | CGS 21680                    | 2-{(2-Carboxyethyl)phenethylamino}⁻N′-ethylcarboxamidoadenosine hydrochloride hydrate      |
| A₂A AR antagonist           | ZM241385                     | 4-{(2-[7-Amino-2-(2-furyl)]1,2,4-triazolo[2,3-ű]1,3,5-triazin-5-ylamino}ethylphenol        |
|                            | SCH-58261                    | 7-(2-Phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-ć]1,2,4-triazolo[1,5-ć]pyrimidine   |
| A₁ AR agonist               | CCPA                         | 2-Chloro-N6-cyclopentyladenosine                                                         |
| A₁ AR antagonist            | DPCPX                        | 8-Cyclopentyl-1,3-dipropylxanthine                                                       |
| eNOSi                       | L-NAME                       | N-Nitroarginine methyl ester                                                             |
| CYP-epoxygenases inhibitor  | MS PPOH                      | N-(Methylsulfonyl)-2-(2-propynylxoxy)-benzenehexanamide                                   |
| CYP-hydroxylase             | DDMS                         | Dibromododecyl methylsulfoximide                                                         |
| Cyclooxygenase inhibitor    | Indomethacin                 |                                                                                            |
| sEH inhibitors             | AUDA                         | 12-(3-adamantan-1-yl-ureido)-dodecanoic acid                                             |
|                            | t-AUCB                       | trans-4-[4-(3-Adamantan-1-yl-ureido)-cyclohexylony]-benzoic acid                          |
| EET antagonist              | 14,15-EEZE                   | 14,15-Epoxyetica-5(z)-enoic acid                                                        |
| 20-HETE inhibitor           | HET0016                      | N-Hydroxy-N’-(4-n-butyl-2-methylphenyl)formamidine                                         |
| K₅₅₇ channel blocker        | Glibenclamide                |                                                                                            |
| Mitochondrial-K₅₅₇ channel blocker | 5-HD                      | 5-Hydroxydecanoate                                                                        |
| PPARγ agonist               | Rosiglitazone                |                                                                                            |
| PPARα antagonist            | GW 6471                      | N-{((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl}propanamide |

Table 1: List of pharmacological drugs commonly used in vascular response investigation.

cerebellum and hippocampal pyramidal neurons [61]. On the other hand, A₂A AR homodimers were reported in HeLa and HEK-293T cells cotransfected with different A₂A AR receptor structures [62]. Ciruela et al. illustrated heterodimerization of A₁ AR and A₂A AR on the cell surface of HEK-293T cells cotransfected with their cDNAs [63]. The activation of A₂A AR via CGS 21680 on these cells reduces the binding affinity of a selective radioligand to bind to A₁ AR [63]. Also, A₁ AR and A₂A AR formed heterodimers in rat astrocyte cultures [64]. The existence of A₁-A₂A AR heterodimers in the CNS was found to maintain neuronal excitability [58]. This finding is interesting because it indicates that ARs may affect each other's ability to respond to different ligands even in the case of what we label as selective ligands, as in the case of CGS 21680, which is a selective agonist of A₂A AR. More interestingly, it was found that GABA uptake was inhibited upon activating A₁ AR whereas GABA uptake was increased upon activating A₂A AR [64]. The data of adenosine receptor dimerization is mostly reported in the CNS; however, the AR oligomerization investigation in the vasculature is still lacking.

To study the mechanism of action of adenosine receptors, we utilized three major strategies: transgenic animal models, special diet, and pharmacological drugs. GENetically modified mice are utilized to discern the physiological importance of adenosine receptors [50]. Thus, most of the reported work in our lab focused on A₂A AR-null, sEH-null, and eNOS-null mice. In the special feeding diet, high salt (HS) and normal salt (NS) intake were used as external factors to investigate how adenosine's effect on vascular response may change. Lastly, the pharmacological reagents were useful since they mimicked the actions and signaling pathway of adenosine. For example, CCPA is a selective A₁ AR agonist that can be used in humans, rats, and mice [43]. DPCPX, a xanthine analog, is a specific A₁ AR antagonist [65]. However, NECA, which was originally thought to be a selective A₂AR agonist, is now considered nonselective for ARs after the development of the more selective A₂A AR agonist CGS 21680 [66] (more examples are available in Table 1). Taking into account the reports of dimerization of ARs, it would be prudent to rethink how we use and interpret the data from these pharmacologic agents. Combining the previous strategies provided a better understanding of A₂A AR's role and function in the vasculature.

Adenosine is a nucleoside generated through metabolic stress as well as high cellular activity [67]. Thus, it increases oxygen supply and decreases oxygen consumption [35]. It is mainly formed by the enzyme 5′-nucleotidase CD73, which dephosphorylates adenosine 5′-monophosphate (AMP) into adenosine that is distributed intracellularly and extracellularly. Intracellularly, adenosine is metabolized by adenosine kinase to AMP, whereas, extracellularly, it is degraded by
adenosine deaminase to inosine [68–70]. Since adenosine can vasodilate and hyperpolarize the vascular smooth muscle cells (VSMC), it is considered an EDHF [71]. There are four adenosine subfamily receptors in the vascular tissue that bind to adenosine, which are A1AR, A2AAR, A2BAR, and A3AR. These receptors are involved in vascular tone regulation via CYP enzymes family which will be discussed in more detail later. Most of the published data so far suggest that the activation of adenosine receptors A2AAR and A2BAR mediates vasodilation in various vessels [14, 15, 72–75], whereas the activation of A1AR and A3AR causes vasoconstriction [55, 56]. Moreover, both A1AR and A2AAR are necessary for maintaining blood pressure (BP) [76].

The inception studies in our lab of adenosine receptors’ role in vascular tone started by studying the vasodilation effect of activating A2AAR in A2AAR+/+ (wild type) and A2AAR−/− (A2AAR knockout) of mouse aorta. NECA (adenosine agonist) and CGS 21680 (a selective A2AAR agonist) caused increased vasodilation in A2AAR+/+ mouse aortae, whereas NECA caused vasoconstriction and CGS 21680 caused neither relaxation nor constriction in A2AAR−/− mouse aortae (see Table 1 for all pharmacological reagents) [15]. These findings were important since they partly led to better understanding of the vasodilatory effect of A2AAR as evident in the lack of vasodilation when CGS 21680, which is a selective A2AAR agonist, was used in A2AAR knockout mice [15]. However, the nonselective nature of NECA meant that, in the absence of A2AAR receptors in A2AAR−/− mice, this compound would activate the other adenosine receptors (A1AR, A2BAR, and A3AR). The vasoconstrictive effect of A1AR, along with the finding that the vasoconstrictive Cyp4a’s expression is increased in A2AAR−/− mice [15], could explain the NECA-mediated vasoconstriction in A2AAR−/− mice [15]. Additionally, the data suggested that A2AAR-mediated vasodilation was endothelium-dependent since NECA-induced vasodilation was observed only in aortic rings with intact endothelium, whereas endothelium-denuded rings responded by contraction [15]. In contrast, Aysjad and Dobson illustrated that adenosine-induced vasodilation in male Sprague- Dawley rats’ thoracic aortic rings was partially endothelium-dependent [77]. This finding is in agreement with other reported studies in different vascular beds such as rat preglomerular microvessels [72, 78], porcine coronary artery wall [79], porcine retinal arterioles [80], rat pial arterioles [81], rat inferior mesenteric artery [82], and human coronary arterioles [83].

Other studies indicated that the activation of A2AAR leads to vascular relaxation via CYP-epoxygenase [15, 75, 84–88]. In these experiments, A2AAR+/+ and A2AAR−/− mice aortae and pharmacological agents such as MS-PPOH (selective CYP-epoxygenase inhibitor), NECA (adenosine agonist), and CGS 21680 (a selective A2AAR agonist) were employed. The observed vasodilation induced by NECA and CGS 21680 was completely inhibited by MS-PPOH, which supports the findings we and others have reported in mouse aortae [15], rat preglomerular microvessels [72], and rat isolated perfused kidney [89]. Moreover, the activation of A2AAR was associated with upregulation of Cyp2c29 (CYP-epoxygenase enzyme of mice species) in the endothelium-dependent relaxation. In comparison, in A2AAR−/− mice, vasoconstriction via Cyp4a (an ω-hydroxylase enzyme) was observed [15]. This pathway was explored by using DDMS and HET-0016 (ω-hydroxylases inhibitors) (see Figure 1 and Table 1). Both inhibitors reversed vascular contraction, which suggested that the induced vasoconstriction in A2AAR−/− mice was mediated by the Cyp4a enzyme [15]. Additionally, the endothelium layer was denuded to investigate its involvement in A2AAR-induced vascular dilation. Vasoconstriction was observed in induced A2AAR aorta; that is, the CGS 21680 agonist effect on A2AAR was abolished in the denuded endothelium [15]. From the previous work and other studies, it is concluded that both CYP-epoxygenases and ω-hydroxylases were involved simultaneously with A2AAR in vascular tone regulation [15, 90].

A group of metabolites have been linked to the actions mediated by adenosine receptors; studies have demonstrated that the vasodilatory effects induced by adenosine through A2AAR and A2BAR are mediated by several physiological factors including NO [80, 91], EETs [92], and ATP-sensitive K+ (KATP) channels [74, 80, 93, 94]. These studies also used pharmacological reagents, such as glibenclamide, for inhibiting the KATP channels as well as potassium channels openers (PCO) such as pinacidil and cromakalim. One of the major effects of the opening of KATP channels in vascular vessels is hyperpolarization of the smooth muscle resulting in vasorelaxation [95, 96]. Moreover, KATP channels were involved in the signaling pathways of adenosine-induced vasodilation as reported by others in coronary arterioles of miniature swine [97], human isolated small coronary arteries [98], rat retinal microvessels [99], porcine coronary artery [100], isolated rat pulmonary artery rings [101], and perfused hydronephrotic rat kidney [102]. Also, Aysjad and Dobson demonstrated that voltage-dependent K+ and KATP are opened in response to A2AAR-induced vasodilation in response to adenosine activation [77]. Using PCO in both A2AAR−/− and A2AAR+/+, vasorelaxation was significantly reduced in A2AAR−/− compared to A2AAR+/+, which indicated a role of sarcolemmal KATP channels with A2AAR+/+ in vascular relaxation [95]. The PCO-induced effect was inhibited by glibenclamide, confirming the role of PCO in opening the KATP channels [95]. Therefore, the induced A2AAR effect through CGS 21680 was blocked by glibenclamide confirming the involvement of sarcolemmal KATP channels in the vasorelaxation process [95].

The involvement of A3AR in vascular relaxation through sarcolemmal KATP channels was investigated. The principle of this study is based on utilizing PCO in A1BAR−/− and A2BAR−/− mice aortae. The A1BAR−/− had a comparable relaxation effect to the A2BAR+/+ (WT), whereas the A2BAR−/− had decreased relaxation compared to A2BAR+/+. Further blocking A2AAR with SCH 58261 (A2AAR antagonist) generated the same response as in the A2AAR−/−.
With the comparable effect observed from both $A_2A$AR and $A_2A$AR$^{-/-}$, it is suggested that the potassium channels mediate the relaxation induced by $A_2A$AR.

It is reported by Ye et al. [92, 103] and Lu et al. [104] that EETs act as activators of $K_{ATP}$ channels. Another study by Ponnath et al. investigated the relationship between EETs and $K_{ATP}$ channels [95]. By blocking the CYP-epoxygenases with MS-PPOH, the relaxation effect induced by pinacidil was greatly decreased. Other laboratories investigated the involvement of NO in $A_2A$AR-$K_{ATP}$ pathway in pig coronary arterioles [74], porcine second-order retinal arterioles [80], and mouse aorta [95]. Their studies suggested that $A_2A$AR-mediated vasodilation was through NO (released by endothelium) and opening of $K_{ATP}$ channels on smooth muscles [74]. A link in the signaling cascade between the $K_{ATP}$ channels and adenosine-mediated vasorelaxation was reported in several vascular beds [97–102]. In our lab, the $K_{ATP}$ channel openers pinacidil and cromakalim produced relaxation in both wild-type ($A_2A$AR$^{+/+}$) and $A_2A$AR knockout ($A_2A$AR$^{-/-}$) mice but were significantly higher in the presence of $A_2A$AR [95]. This finding confirmed that adenosine-mediated vasorelaxation is mediated by $K_{ATP}$ channels [95]. Moreover, we demonstrated that NO played a role in the relaxation induced by pinacidil [95]. When $l$-NAME (NO synthase inhibitor) was used in wild type ($A_2A$AR$^{+/+}$) in the presence of pinacidil, the vascular relaxation was decreased to a level comparable to that in $A_2A$AR$^{-/-}$ mice [95]. Based on that, the signaling mechanism of adenosine at the $A_2A$AR for aortic vascular relaxation involved CYP-epoxygenases through the following mediators arranged in order: EETs, nitric oxide (NO), and the opening of sarcolemmal $K_{ATP}$ channels in the endothelium [95].

The involvement of 20-HETE with $A_1$AR was also investigated in vascular tone of mouse aorta [105]. Since 20-HETE is the active metabolite of AA through Cyp4a and is a potent vasoconstrictor [88], HET0016 was used to inhibit Cyp4a activity. As a result, the vascular contraction of induced $A_1$ was notably decreased in $A_2A$AR$^{+/+}$ and $A_2A$AR$^{-/-}$, suggesting that Cyp4a is downstream of $A_1$AR [105].
Other studies were conducted to reveal the involvement of CYP enzymes and signaling pathways in \(A_{2\alpha}AR^{+/+}\) and \(A_{2\alpha}AR^{-/-}\) vascular endothelium of mice aortae. First, in \(A_{2\alpha}AR^{-/-}\) mice, the data demonstrated vasoconstriction induced by Cyp4a through 20-HETE accompanied by upregulation of \(A_1\) AR, which mainly activates protein kinase C (PKC-\(\alpha\)) and mitogen-activated protein kinase (MAPK) [105]. This effect on PKC is mediated by Gxi coupling [106]. The involvement of PKC-\(\alpha\) and MAPK in induced \(A_1\) AR was also determined. In PKC-\(\alpha\), using G\(\delta\)-6976, a selective PKC-\(\alpha\) inhibitor, it primarily weakens the vasoconstriction response mediated by \(A_1\) AR in both \(A_{2\alpha}AR^{+/+}\) and \(A_{2\alpha}AR^{-/-}\) aortae [105]. However, the MAPK inhibitor, PD-98059, was used first to treat aortae, followed by CCPA to activate \(A_1\) AR. PD-98059 totally blocked \(A_1\) AR-induced vasoconstriction by CCPA suggesting the involvement of MAPK in vasoconstriction. Ponnuth et al. [105] and Ansari et al. [107] suggested that \(A_1\) AR-induced vascular contraction is through Cyp4a, which generates 20-HETE, and leads to the activation of PKC-\(\alpha\), which phosphorylates MAPK.

We mentioned earlier that the adenosine receptors, like other GPRCs, can interact with each other through dimerization. Ponnuth et al. reported that CCPA (a selective \(A_1\) agonist) produced significantly higher contraction in \(A_{2\alpha}AR^{-/-}\) compared to wild-type (\(A_{2\alpha}AR^{+/+}\)) mice [105]. It is also reported by the same authors [105] that the basal protein expression of \(A_1\) AR was higher in \(A_{2\alpha}AR^{-/-}\) mice compared to \(A_{2\alpha}AR^{+/+}\) mice [105]. This overexpression is due to lack of \(A_2\) \(\alpha\) AR inhibition effect over \(A_1\) AR [105]. The more enhanced contraction in \(A_{2\alpha}AR^{-/-}\) mice by an \(A_1\) AR agonist could be explained by the increased expression of \(A_1\) AR in this mouse genotype [105] and a possible lack of interaction, as suggested by the reported dimerization, between \(A_1\) AR and \(A_2\) \(\alpha\) AR due to the absence of the latter [58, 63, 64].

High salt (HS) intake is considered one of the risk factors for many diseases such as hypertension [108, 109]. HS also acts as an external factor to affect vascular tone, and therefore it is important to study its potential involvement with \(A_{2\alpha}AR\) and its downstream mechanism in vascular tone regulation, to which we turn our focus now. We previously reported a connection between adenosine receptors activation, particularly \(A_2\) \(\alpha\), and high dietary salt intake in mouse aorta [14, 33, 76] as done by others in isolated perfused rat kidney [89]. Therefore, the role of \(A_{2\alpha}AR\) in high salt diet was investigated [76]. Data showed upregulation of \(A_{2\alpha}AR\) expression in response to high salt intake [14, 76, 110] and subsequent increase in \(A_{2\alpha}AR\)-induced vasorelaxation [14, 33, 72, 89, 110]. In contrast, \(A_1\) AR, which is involved in vasoconstriction, was downregulated in high salt-fed mice [14, 110]. Moreover, the produced adenosine levels were increased by HS diet ingestion in mice [111] and rats in other studies [33, 110, 112, 113].

Another study showed a relationship between activated \(A_{2\alpha}AR\) and HS diet [14, 16, 78]. The data suggested that HS in \(A_{2\alpha}AR^{+/+}\) improves \(A_{2\alpha}AR\)-induced relaxation due to the enhanced CYP-epoxygenases activity, which produce more EETs. On the other hand, in \(A_{2\alpha}AR^{-/-}\), the HS caused vascular contraction due to the lower level of CYP-epoxygenases activity and enhanced level of \(A_1\) AR [76].

The use of NECA (a nonselective adenosine analog) and CGS 21680 (selective \(A_2\) \(\alpha\) AR agonist) resulted in enhanced aortic vasodilation in HS-fed versus NS-fed mice [14]. The close relationship of \(A_{2\alpha}AR\) either activated or induced via pharmacological drug and HS diet provided a better understanding of vascular modulation. Therefore, we investigated \(A_{2\alpha}AR^{+/+}\) and \(A_{2\alpha}AR^{-/-}\) mice in HS and normal salt (NS) diet study [76]. In the presence of \(A_{2\alpha}AR\), data demonstrated that HS increases \(A_{2\alpha}AR\)-induced vasodilation. On the other hand, in the knockout mice, HS increases contraction through increased levels of \(A_1\) AR [76]. The HS and NS diet studies confirm the involvement of \(A_{2\alpha}AR\) in vascular tone regulation. The \(A_{2\alpha}AR\) response to HS-fed mice is possibly adaptive since it showed upregulation of \(A_{2\alpha}AR\) and increased vasodilation of mice aortae [76] as previously demonstrated in glomerular vessels of HS-fed mice [110].

Overall, many experiments conducted by our lab and others have repeatedly confirmed the important role of adenosine, through its receptor subtypes, in vascular tone regulation. Also, they elucidated much of the downstream signaling pathways, which include CYP enzymes, EETs, \(\omega\)-HETEs, PPARs, and \(K_{ATP}\) channels.

### 4. The Role of CYP-Epoxygenases in Vascular Tone Modulation

The investigated downstream mechanism starting from \(A_{2\alpha}AR\) and \(A_1\) AR until CYP enzymes was discussed above in detail. Now, we will continue the discussion of the other steps in the downstream cascade from CYPs until the hyperpolarization which ultimately leads to vascular smooth muscle relaxation. In this section, we will explore the involvement of CYP enzymes, sEH, PPAR\(\gamma\), and PPAR\(\alpha\) in vascular tone regulation (Figure 1) under normal and high salt conditions in the aorta and their roles in coronary reactive hyperemia (CRH) in response to ischemia.

\(A_2\) \(\alpha\) AR-mediated vascular response involves CYP enzymes, which are related to cytochrome P450s (CYP450) enzyme family [90, 114]. CYP450 family are divided into two types, CYP-epoxygenases (CYP2C and CYP2J) and \(\omega\)-hydroxylases (CYP4A and CYP4F), that are involved in maintaining vasculature tone [90, 114, 115]. Although both enzymes are from the same CYP450 family, they produce different metabolites from AA with widely different physiological functions. For instance, CYP-epoxygenases metabolize AA to generate epoxyeicosatrienoic acids (EETs), which have a vasodilatory effect [116]. On the other hand, the \(\omega\)-hydroxylases convert AA to 20-hydroxyeicosatetraenoic acid (20-HETE), which is a vasoconstrictor [117]. Both groups of metabolites from AA are natriuretic agents.

EETs have four different regioisomers, 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET, and have many biological functions; for example, they are released from endothelial cells and act as EDHFs to produce vasodilation through hyperpolarization [118, 119]. Their relaxation of vascular
smooth muscle cell is believed to be through the activation of large conductance Ca\(^{2+}\)-activated K\(^+\) channels (BK\(_{Ca}\)) [118, 119]. Moreover, EETs have cardioprotective effects in response to ischemia/reperfusion injury (i.e., EETs reduced heart injury after ischemia) [120]. The vasodilatory effect of EETs is reported in different vascular beds such as the brain [121], preglomerular vasculature of the kidney [122], conduit arteries [14, 15, 32, 33], and intestines [116].

EETs are further metabolized to dihydroxyicosatrienoic acids (DHETs), which are less active, through soluble epoxide hydrolase (sEH), the primary metabolic pathway for EETs [123]. DHETs were shown to be either inactive or less active than their parent compounds EETs on smooth muscle cells [124]. Other enzyme families involved in AA metabolism are cyclooxygenase (COX) and lipoxygenase (LOX), in which they generate prostanoids and midchain HETEs, respectively. Overall, the metabolites generated by CYPs enzymes from AA are known as oxylipins.

The link between A\(_2\)AR and CYP-epoxygenase was demonstrated earlier; most collected data so far demonstrated the relationship among A\(_2\)AR, CYP-epoxygenase, sEH, and peroxisome proliferator-activated receptor gamma (PPAR\(_\gamma\)) in addition to the involvement of A\(_1\)AR and PPAR\(_\alpha\) in sEH\(^{+/+}\) (wild type) and sEH\(^{-/-}\) (knockout) in regulating the vascular tone of mice aortae [32]. In sEH\(^{-/-}\), the vascular relaxation induced by adenosine was driven by the upregulation of A\(_2\)AR, CYP2J, and PPAR\(_\gamma\) and downregulation of A\(_{1}\)AR and PPAR\(_\alpha\) [32]. However, in sEH\(^{+/+}\), adenosine produced vasoconstriction through PPAR\(_\alpha\) [32]. Nayeeom et al. illustrated that CGS 21680-induced relaxation in sEH\(^{-/-}\) mice was induced by A\(_2\)AR activation, which resulted in CYP-epoxygenases generation of EETs. Moreover, CGS 21680-induced vasodilation was inhibited by the EET antagonist 14,15-EEZE in sEH\(^{-/-}\) mice. This finding is in agreement with previous data in which the adenosine-induced vasodilation was blocked by 14,15-EEZE in A\(_2\)\(A\(_R^{+/-}\) mouse aorta [14]. Likewise, Gauthier et al. confirmed the relationship between A\(_2\)AR and sEH in bovine coronary arteries [125]. Additionally, in sEH\(^{-/-}\) mouse aorta, CYP2J5 protein level was upregulated compared to sEH\(^{+/+}\), suggesting that the adenosine-induced vasodilation requires CYP-epoxygenases, such as CYP2J [32].

The sEH inhibitors were valuable in linking A\(_2\)AR with sEH enzyme in vascular tone regulation. Herein, blocking sEH, which converts EETs (vasodilator) to DHETE (inactive) by AUDA or t-AUCB, further enhanced the vascular relaxation induced by CGS 21680 [32]. The strong response was suggested to be due to an increase in EET level based on other published data [126]. Moreover, the use of EETs antagonist, 14,15-EEZE, blocked the vascular relaxation induced by CGS 21680, which confirmed that the enhanced vasodilation was due to the increased effect of EET [32].

We evaluated the effect of high salt intake and the role of CYP-epoxygenases in vascular tone regulation [76]. We mentioned above the significance of A\(_2\)AR and A\(_1\)AR in relation to HS intake in vascular modulation. The role of cyclooxygenase (COX) was investigated by using A\(_2\)AR\(^{+/+}\) and A\(_2\)AR\(^{-/-}\) mice aortae in vascular response. By treating HS-fed A\(_2\)AR\(^{+/+}\) with CGS 21680, in the presence or absence of a COX inhibitor and an eNOS inhibitor, the same vasodilatation was produced. This can be explained by the notion that vascular dilatation in response to CGS 21680 was COX- and NO-independent [76]. Moreover, the use of EETs antagonist inhibited CGS 21680-induced vasodilation. This illustration is in agreement with previous studies [14, 15, 72, 78]. Additionally, in HS-fed A\(_2\)AR\(^{-/-}\) mice, the level of CYP2c29, which generates EETs, was increased versus NS-fed mice [76]. In comparison with A\(_2\)AR\(^{-/-}\), the expression level of CYP2c29 was reduced in HS-fed versus NS diet A\(_2\)AR\(^{+/+}\). This observation suggests that CYP-epoxygenases, such as cyp2c29, have a substantial role in mediating vascular relaxation downstream of A\(_2\)AR in response to HS intake. In rat studies of HS-fed A\(_2\)AR\(^{-/-}\) [110], there was no increase of CYP-epoxygenase in response to HS, which supports this finding. Although the findings of Arsyad and Dobson supported our finding that COX was not involved in adenosine-induced vasodilatation [77], they contrasted our finding that CGS 21680-induced vasodilation was NO-independent by demonstrating that the adenosine-induced vasodilatation in thoracic aortic rings of male Sprague-Dawley rats was NO-dependent [77].

We sought to search for more evidence in our research on vascular tone regulation and moved a step forward from in vitro studies (vessel organ bath) to the ex vivo experiment Langendorff (isolated heart). This extension added more valuable understanding by bringing research data and hypothesis a step closer to translational, functional, and applied science. Herein, we evaluated the role of CYP-epoxygenases and sEH in coronary artery response to ischemia, or coronary reactive hyperemia (CRH), which is a protective mechanism to prevent potential damage to the heart due to ischemic insult [124]. When the heart is exposed to a brief ischemia, coronary blood flow immediately increases afterwards to compensate for the lack of blood supply and avoid any toxic metabolites build-up in the heart [127, 128]. We investigated the pharmacological inhibition on CYP-epoxygenases and sEH using two different genotypes of mice, sEH null (sEH\(^{-/-}\)) and wild type (sEH\(^{+/+}\)), using Langendorff (isolated heart) technique [124]. The inhibition of CYP-epoxygenases by MS-PPOH reduced CRH, whereas the inhibition of sEH by t-AUCB enhanced CRH in isolated mouse heart [124]. As mentioned previously, CYP-epoxygenases convert AA to EETs. It is reported that EETs were involved in insulin-induced augmentation of skeletal muscle perfusion. The study used MS-PPOH (CYP-epoxygenase inhibitor) to block EETs synthesis and confirmed EETs involvement in the augmentation of skeletal muscle perfusion [78]. Fleming reported that the majority of P450 enzymes are highly distributed in coronary arteries and small arterioles [119]. By blocking CYP-epoxygenases pathway, the synthesis of EETs was inhibited, and the protective CRH was attenuated as well [124]. On the other hand, by treating the heart with t-AUCB, CRH was enhanced versus...
nontreated WT mice [124]. In treating sEH−/− mice compared with nontreated sEH+/− mice by t-AUCB, there were no significant differences, which emphasizes the selectivity of sEH inhibitor, t-AUCB, in CRH response to brief ischemia [124].

The vasodilatory and cardioprotective roles EETs are reiterated in a number of blood vessels. The release of EETs was also linked to A2A AR activation and was shown to be responsive to changes in EETs generating enzymes (CYP-epoxygenases) and EETs deactivating enzyme (sEH) [76]. These data further support the notion of finding clinical applications for these beneficial metabolites (EETs) through targeting different enzymes in their pathway.

5. The Role of PPARγ in A2A AR-Induced Vascular Relaxation

PPARs are one of the downstream targets of EETs. Most of the epoxygenases effects are through PPARs stimulation; that is, PPARs activation produces similar effects to those of EETs and A2A AR [129]. For instance, the stimulation of PPARs induces vascular tone regulation, vascular cell proliferation, and cell relocation [130, 131]. Moreover, one of the functions of PPARγ in the endothelial cell as reported by Liu et al. [126] is an anti-inflammatory effect. In diabetic mice study, activation of PPARγ caused endothelium-dependent vasodilation, which was found in nondiabetic mice (+db/+m) [132]. Moreover, others suggested that PPARs have a role in adipogenesis, insulin sensitivity, and regulation of blood vessels tone [133]. In our sEH+/−-sEH−/− mouse study, the protein level of PPARγ was upregulated, and the proteins level of PPARγ was downregulated in response to CGS 21680 in sEH−/− versus sEH+/− mouse aorta [76, 129]. Therefore, these data suggest that PPARγ is involved in CGS 21680-induced vasodilation in sEH−/−, whereas the activation of PPARγ causes vasocontraction [76, 129] (Figure 1). It was confirmed that the PPARγ agonist (GW 7647) reduced the relaxation of CGS 21680 induced dose-dependently. Additionally, the vascular response induced by CGS 21680 was remarkably blocked by PPARγ antagonist in sEH−/− [32]. Overall, PPARγ in the vascular endothelial cell is activated by EETs to cause vascular relaxation. Since PPARγ is linked with EETs, which in turn are generated by enhanced CYP-epoxygenase activity via A2A AR-induced vascular response, we reported the role of PPARγ in HS-fed A2A AR+/− and A2A AR−/− mice. In addition, we also reported the interplay between A2A AR, sEH, EETs, PPARγ, and KATP in vascular response [129]. In this study, CGS 21680, T0070907, rosiglitazone, AUDA, and glibenclamide were utilized. The data demonstrated in HS-fed A2A AR−/− that inhibiting PPARγ led to an increase in CGS 21680-induced vasodilation, which links A2A AR with PPARγ [129]. Moreover, PPARγ antagonist attenuated AUDA-induced vascular relaxation response, which confirms the link between EETs (through the sEH inhibitor AUDA) and PPARγ. The KATP channel blocker also attenuated the vasodilation-induced rosiglitazone; this establishes a connection between PPARγ and KATP. On the other hand, in HS-fed A2A AR−/−, the HS-induced vascular contraction was attenuated by the sEH inhibitor AUDA [129]. Overall, the vascular response to mediators, such as PPARγ agonist, PPARγ-antagonist, sEH inhibitors, and KATP channel blocker, was altered in response to HS feeding in both A2A AR−/− and A2A AR+/+. These data indicated that these mediators (EETs, PPARγ, and KATP channels) are downstream of A2A AR [129].

In the isolated mouse heart, the data showed that the effect of CRH was decreased by PPARγ antagonist (T0070907), whereas PPARγ agonist (rosiglitazone) enhanced it [124]. Since the t-AUCB-enhanced CRH was reduced by the PPARγ antagonist, T0070907, in WT mouse heart, a link between EETs and PPARγ is more likely [124]. This is an indication that the modulation of CRH involves PPARγ receptors through CYP-epoxygenase-EET pathway [124]. Other studies also reported that PPARγ receptors are induced by EETs [129, 134–136]. Liu et al. suggested that activation of PPARγ increased retention of EETs in endothelial cells and enhanced the anti-inflammatory effect upon using a selective sEH inhibitor [136]. The previously reported data with our finding illustrated that PPARγ activation is downstream of CYP-epoxygenase-EET pathway to mediate CRH.

6. Conclusion

The vascular endothelium is a complex tissue with numerous functions and roles that potentially affect all body organs and systems. The main physiologic as well as pathologic role of the vascular endothelium is related to its regulation of blood flow, which is known as vascular tone regulation. The complicated process of vascular tone regulation involves receptors, enzymes, ion channels, and many mediators that have not been fully disclosed. Therefore, understanding the vascular tone modulation by different pharmacological reagents and polymorphic or allelic variant models is very significant. Particularly in mice aortae, activation of A2A AR triggers multiple steps to elicit a vascular response. A2A AR activation is associated with enhanced CYP-epoxygenases activity, which generate EETs from AA, and opening of sarcolemmal KATP channels. The reported data suggest that CYP-epoxygenases, EETs, PPARγ, and sarcolemmal KATP channels are involved in vascular tone regulation. By thoroughly understanding the mechanisms controlling vascular tone regulation, we will likely become closer to finding potential targets for pharmacologic intervention for treating pathologies affected by or involving the vascular endothelium.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to thank Ahmad Hanif, Ph.D., for editing. This work was supported by the National Institutes of Health (NIH; Grant HL-114559) to Mohammed A. Nayeem.
References
[1] A. Sandoo, J. J. C. S. V. van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas, "The endothelium and its role in regulating vascular tone," *The Open Cardiovascular Medicine Journal*, vol. 4, pp. 302–312, 2010.
[2] B. M. Egan, Y. Zhao, and R. N. Axon, "US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008," *The Journal of the American Medical Association*, vol. 303, no. 20, pp. 2043–2050, 2010.
[3] L.-W. Lehman, M. Saeed, G. Moody, and R. Mark, "Hypotension as a risk factor for acute kidney injury in ICU patients," *Computing in Cardiology*, vol. 37, pp. 1095–1098, 2010.
[4] C. A. Hübner, B. C. Schroeder, and H. Ehmke, "Regulation of vascular tone and arterial blood pressure: role of chloride transport in vascular smooth muscle," *Pflugers Archiv European Journal of Physiology*, vol. 467, no. 3, pp. 605–614, 2015.
[5] C. M. Lawes, S. V. Hoorn, and A. Rodgers, "Global burden of blood-pressure-related disease, 2001," *The Lancet*, vol. 371, no. 9623, pp. 1513–1518, 2008.
[6] D. Konukoğlu and H. Uzun, *Endothelial Dysfunction and Hypertension*, Springer, Boston, Mass, USA.
[7] M. S. Fernández-Alfonso, "Regulation of vascular tone: The fat connection," *Hypertension*, vol. 44, no. 3, pp. 255–256, 2004.
[8] D. B. Cines, E. S. Pollok, C. A. Buck et al., "Endothelial cells in physiology and in the pathophysiology of vascular disorders," *Blood*, vol. 91, no. 10, pp. 3527–3561, 1998.
[9] L. Ghitescu and M. Robert, "Diversity in unity: The biochemical composition of the endothelial cell surface varies between the vascular beds," *Microscopy Research and Technique*, vol. 57, no. 5, pp. 381–389, 2002.
[10] H. G. Augustin, D. H. Kozian, and R. C. Johnson, "Differentiation of endothelial cells: Analysis of the constitutive and activated endothelial cell phenotypes," *BioEssays*, vol. 16, no. 12, pp. 901–906, 1994.
[11] H. Wolinsky, "A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherosogenesis," *Circulation Research*, vol. 47, no. 3, pp. 301–311, 1980.
[12] R. Jay Widmer and A. Lerman, "Endothelial dysfunction and cardiovascular disease," *Global Cardiology Science and Practice*, vol. 2014, no. 3, pp. 291–308, 2014.
[13] R. P. Brandes, F.-H. Schmitz-Winnenthal, M. Félotou et al., "An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 17, pp. 9747–9752, 2000.
[14] M. A. Nayeem, D. S. Ponnoth, M. A. Boegehold, D. C. Zeldin, J. R. Falck, and S. J. Mustafa, "High-salt diet enhances mouse aortic relaxation through adenosine A2A receptor via CYP epoxygenases," *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, vol. 296, no. 3, pp. R567–R574, 2009.
[15] M. A. Nayeem, S. M. Poloyac, J. R. Falck et al., "Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice," *American Journal of Physiology - Heart and Circulatory Physiology*, vol. 295, no. 5, pp. H2068–H2078, 2008.
[16] M. A. Nayeem, D. C. Zeldin, M. A. Boegehold et al., "Modulation of vascular response mediated through adenosine A2A receptor: role of CYP epoxygenase and soluble epoxide hydrolase," *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, vol. 299, no. 1, pp. R325–R333, 2010.
[17] W. T. Wong, S. L. Wong, X. Y. Tian, and Y. Huang, "Endothelial dysfunction: The common consequence in diabetes and hypertension," *Journal of Cardiovascular Pharmacology*, vol. 55, no. 4, pp. 300–307, 2010.
[18] M. Félotou and P. M. Vanhoutte, "Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture)," *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 291, no. 3, pp. H985–H1002, 2006.
[19] D. H. Endemann and E. L. Schiffrin, "Endothelial dysfunction," *Journal of the American Society of Nephrology*, vol. 15, no. 8, pp. 1983–1992, 2004.
[20] S. Taddel, L. Ghiadoni, A. Virdis, D. Versari, and A. Salvetti, "Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies," *Current Pharmaceutical Design*, vol. 9, no. 29, pp. 2385–2402, 2003.
[21] M. H. Laughlin, S. C. Newcomer, and S. B. Bender, "Importance of hemodynamic forces as signals for exercise-induced changes in endothelial cell phenotype," *Journal of Applied Physiology*, vol. 104, no. 3, pp. 588–600, 2008.
[22] W. T. Cade, "Diabetes-related microvascular and macrovascular diseases in the physical therapy setting," *Physical Therapy*, vol. 88, no. 11, pp. 1322–1335, 2008.
[23] F. Addabbo, M. Montagnani, and M. S. Goligorsky, "Mitochondria and reactive oxygen species," *Hypertension*, vol. 53, no. 6, pp. 885–892, 2009.
[24] A. Hirose, T. Tanikawa, H. Mori, Y. Okada, and Y. Tanaka, "Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway," *FEBS Letters*, vol. 584, no. 1, pp. 61–66, 2010.
[25] P. Rajendran, T. Rengaranjan, J. Thangavel et al., "The vascular endothelium and human diseases," *International Journal of Biological Sciences*, vol. 9, no. 10, pp. 1057–1069, 2013.
[26] M. A. Gimbrone, "Vascular endothelium, hemodynamic forces, and atherogenesis," *American Journal of Pathology*, vol. 155, no. 1, pp. 1–5, 1999.
[27] M. A. Gimbrone, "The Gordon wilson lecture: understanding vascular endothelium: a pilgrim's progress: endothelial dysfunction, biomechanical forces and the pathobiology of atherosclerosis," *Transactions of the American Clinical and Climatological Association*, vol. 121, pp. 115–127, 2010.
[28] P. Libby, P. M. Ridker, and G. K. Hansson, "Inflammation in atherosclerosis: from pathophysiology to practice," *Journal of the American College of Cardiology*, vol. 54, no. 23, pp. 2129–2138, 2009.
[29] C. S. T. Hilaire, S. H. Carroll, H. Chen, and K. Ravid, "Mechanisms of induction of adenosine receptor genes and its functional significance," *Journal of Cellular Physiology*, vol. 218, no. 1, pp. 35–44, 2009.
[30] G. Shaikh and B. Cronstein, "Signaling pathways involving adenosine A(2A) and A(2B) receptors in wound healing and fibrosis," *Purinergic Signalling*, vol. 12, no. 2, pp. 191–197, 2016.
[31] M. A. Nayeem, M. A. Boegehold, and S. J. Mustafa, "Adenosine A2A receptor mediated aortic relaxation in mice fed high salt: role of CYP epoxygenase," *The FASEB Journal*, vol. 21, no. 6, pp. A899–A900, 2007.
[32] M. A. Nayeem, I. Pradhan, S. J. Mustafa, C. Morisseau, J. R. Falk, and D. C. Zeldin, "Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ," *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, vol. 304, no. 1, pp. R23–R32, 2013.

[33] M. A. Nayeem, D. C. Zeldin, M. A. Boegehold, and J. R. Falk, "Salt modulates vascular response through adenosine A2A receptor in ENOS-null mice: Role of CYP450 epoxygenase and soluble epoxide hydrolase," *Molecular and Cellular Biochemistry*, vol. 350, no. 1-2, pp. 101–111, 2011.

[34] M. A. Nayeem, G. P. Matherne, and S. J. Mustafa, "Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (AIAR). Role of AIAR, iNOS and K(ATP) channels," *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 367, no. 3, pp. 219–226, 2003.

[35] H. Labazi, S. L. Tilley, C. Ledent, and S. J. Mustafa, "Role of adenosine receptor(s) in the control of vascular tone in the mouse pudendal artery," *Journal of Pharmacology and Experimental Therapeutics*, vol. 356, no. 3, pp. 673–680, 2016.

[36] K. Fuxe, D. O. Borroto-Escuela, W. Romero-Fernandez et al., "On the role of volume transmission and receptor-receptor interactions in social behaviour: Focus on central catecholamine and oxytocin neurons," *Brain Research*, vol. 1476, pp. 119–131, 2012.

[37] G. Navarro, D. O. Borroto-Escuela, K. Fuxe, and R. Franco, "Purinergic signaling in Parkinson’s disease. Relevance for treatment," *Neuropharmacology*, vol. 104, pp. 161–168, 2016.

[38] D. O. Borroto-Escuela, J. Carlsson, P. Ambrogini et al., "Understanding the role of gpcr heteroreceptor complexes in modulating the brain networks in health and disease," *Frontiers in Cellular Neuroscience*, vol. II, p. 37, 2017.

[39] L. T. Woods, D. Ajit, J. M. Camden, L. Erb, and G. A. Weisman, "Purinergic receptors as potential therapeutic targets in Alzheimer’s disease," *Neuropharmacology*, vol. 104, pp. 169–179, 2016.

[40] M. Matos, H.-Y. Shen, E. Augusto et al., "Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to Schizophrenia," *Biological Psychiatry*, vol. 78, no. II, pp. 763–774, 2015.

[41] X. Guitart, J. Bonaventura, W. Rea et al., "Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease," *Neurobiology of Disease*, vol. 96, pp. 47–53, 2016.

[42] A. Rahman, "The role of adenosine in Alzheimer’s disease," *Current Neuropharmacology*, vol. 7, no. 3, pp. 207–216, 2009.

[43] B. B. Fredholm, A. P. Izzerman, K. A. Jacobson, K. N. Klotz, and J. Linden, "International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors," *Pharmacological Reviews*, vol. 53, no. 4, pp. 527–552, 2001.

[44] J. Linden, "Structure and function of AI adenosine receptors," *FASEB Journal*, vol. 5, no. 12, pp. 2668–2676, 1991.

[45] A. M. Sebastião and J. A. Ribeiro, "Adenosine A2 receptor-mediated excitatory actions on the nervous system," *Progress in Neurobiology*, vol. 48, no. 3, pp. 167–189, 1996.

[46] D. Boison, "Adenosine as a neuromodulator in neurological diseases," *Current Opinion in Pharmacology*, vol. 8, no. 1, pp. 2–7, 2008.

[47] X. X. Li, T. Nomura, H. Aihara, and T. Nishizaki, "Adenosine enhances glial glutamate efflux via A2a adenosine receptors," *Life Sciences*, vol. 68, no. 12, pp. 1343–1350, 2001.

[48] A. Melani, S. Cipriani, M. G. Vannucchi et al., "Selective adenosine A2A receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia," *Brain*, vol. 132, no. 6, pp. 1480–1495, 2009.

[49] B. D. Hettinger, A. Lee, J. Linden, and D. L. Rosin, "Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum," *Journal of Comparative Neurology*, vol. 431, no. 3, pp. 331–346, 2001.

[50] B. B. Fredholm, A. P. Izzerman, K. A. Jacobson, J. Linden, and C. E. Müller, "International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update," *Pharmacological Reviews*, vol. 63, no. 1, pp. 1–34, 2011.

[51] M. D. L. Ruiz, Y. H. Lim, and J. Zheng, "Adenosine A1 receptor as a drug discovery target," *Journal of Medicinal Chemistry*, vol. 57, no. 9, pp. 3623–3650, 2014.

[52] P. J. Gebicke-Haerter, F. Christoffel, J. Timmer, H. Northhoff, M. Berger, and D. Van Calker, "Both adenosine A1- and A2A-receptors are required to stimulate microglial proliferation," *Neurochemistry International*, vol. 29, no. 1, pp. 37–42, 1996.

[53] K. Biber, K.-N. Klotz, M. Berger, P. J. Gebicke-Härter, and D. Van Calker, "Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression," *Journal of Neuroscience*, vol. 17, no. 13, pp. 4956–4964, 1997.

[54] T. Othman, H. Yan, and S. A. Rivkees, "Oligodendrocytes express functional AI adenosine receptors that stimulate cellular migration," *Glia*, vol. 44, no. 2, pp. 166–172, 2003.

[55] P. B. Hansen and J. Schnerrmann, "Vasoconstrictor and vasodilator effects of adenosine in the kidney," *American Journal of Physiology - Renal Physiology*, vol. 285, no. 4, pp. F590–F599, 2003.

[56] P. B. Hansen, H. Castrop, J. Briggs, and J. Schnerrmann, "Adenosine induces vasoconstriction through Gi-dependent activation of phospholipase C in isolated perfused afferent arterioles of mice," *Journal of the American Society of Nephrology*, vol. 14, no. 10, pp. 2457–2465, 2003.

[57] D. Preti, P. G. Baraldi, A. R. Moorman, P. A. Borea, and K. Varani, "History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents," *Medicinal Research Reviews*, vol. 35, no. 4, pp. 790–848, 2015.

[58] S. Sheth, R. Brito, D. Mukherjea, L. P. Rybak, and V. Ramkumar, "Adenosine receptors: Expression, function and regulation," *International Journal of Molecular Sciences*, vol. 15, no. 2, pp. 2024–2052, 2014.

[59] S. Ferré, R. Baler, M. Bouvier et al., "Building a new conceptual framework for receptor heteromers," *Nature Chemical Biology*, vol. 5, no. 3, pp. 131–134, 2009.

[60] F. Ciruela, V. Casado, J. Mallol, E. I. Canela, C. Lluis, and R. Franco, "Immunological identification of AI adenosine receptors in brain cortex," *Journal of Neuroscience Research*, vol. 42, no. 6, pp. 818–828, 1995.

[61] K. Namba, T. Suzuki, and H. Nakata, "Immunogold electron microscopic evidence of in situ formation of homo- and heteromeric purinergic adenosine AI and P2Y2 receptors in rat brain," *BMC Research Notes*, vol. 3, p. 323, 2010.

[62] M. Canals, J. Burgueño, D. Marcellino et al., "Homodimerization of adenosine A2A receptors: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer," *Journal of Neurochemistry*, vol. 88, no. 3, pp. 726–734, 2004.
[63] S. Cristóvão-Ferreira, G. Navarro, M. Brugarolas et al., “Presynaptic control of striatal glutamatergic neurotransmission by adenosine $A_2A$- $A_3$ receptor heteromers,” Journal of Neuroscience, vol. 26, no. 7, pp. 2080–2087, 2006.

[64] S. Cristóvão-Ferreira, G. Navarro, M. Brugarolas et al., “$A_1$R-$A_2$R heteromers coupled to G$_i$ and G$_{o}$ proteins modulate GABA transport into astrocytes,” Purinergic Signalling, vol. 9, no. 3, pp. 433–449, 2013.

[65] B. Johansson, L. Halldner, T. V. Dunwiddie et al., “Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9407–9412, 2001.

[66] A. J. Hutchison, R. L. Webb, H. H. Oei, G. R. Ghai, M. B. Zimmerman, and M. Williams, “CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity,” Journal of Pharmacology and Experimental Therapeutics, vol. 251, no. 1, pp. 47–55, 1989.

[67] D. A. Carroll, A. B. Doumad, J. Li, M. K. Cheng, J. R. Falck, and J. C. McGiff, “Adenosine $A_2A$ receptor vasodilation of rat preglomerular microvessels is mediated by EFTs that activate the cAMP/PKA pathway,” American Journal of Physiology - Renal Physiology, vol. 291, no. 1, pp. F155–F161, 2006.

[68] T. W. Hein, L. Belardinelli, and L. Kuo, “Adenosine A2A receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium,” American Journal of Physiology - Cardiovascular Physiology, vol. 296, no. 5 Pt 2, pp. H1608–H1625, 2009.

[69] H. Ohata, S. Cao, and R. C. Koehler, “Contribution of adenosine $A_1$ and $A_2A$ receptors and heme oxygenase to AMPA-induced dilation of pial arterioles in rats,” American Journal of Physiology - Regulatory Integrative and Comparative Physiology, vol. 291, no. 3, pp. R728–R735, 2006.

[70] M. Radenkovic, L. Grbovic, S. Pasic, and D. Stojic, “Isolated rat inferior mesenteric artery response to adenosine: possible participation of Na+/K+-ATPase and potassium channels,” Pharmacological Reports, vol. 57, no. 6, pp. 824–832, 2005.

[71] S. J. Mustafa and A. O. Askar, “Evidence suggesting an R-type adenosine receptor in bovine coronary arteries,” Journal of Pharmacology and Experimental Therapeutics, vol. 232, no. 1, pp. 49–56, 1985.

[72] S. J. Mustafa, R. R. Morrison, B. Teng, and A. Pelleg, “Adenosine receptors and the heart: Role in regulation of coronary blood flow and cardiacelectrophysiology,” Handbook of Experimental Pharmacology, vol. 193, pp. 161–188, 2009.

[73] H. Fleming, “Cytocrome p450 and vascular homeostasis,” Circulation Research, vol. 89, no. 9, pp. 753–762, 2001.

[74] Y. Ishibashi, D. J. Duncker, J. Zhang, and R. J. Bache, “ATP-sensitive $K_+$ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise,” Circulation Research, vol. 82, no. 3, pp. 346–359, 1998.
by 14,15-epoxyeicosatrienoic acid,” *American Journal of Physiology - Heart and Circulatory Physiology*, vol. 290, no. 4, pp. H1326–H1336, 2006.

[93] L. Kuo and J. D. Chancellor, “Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATP channels in endothelium,” *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 269, no. 2, pp. H541–H549, 1995.

[94] V. N. Mulafova-Yambolieva and K. D. Keef, “Adenosine-sensitive hyperpolarization in guinea pig coronary artery involves $A_2\alpha$ receptors and $K_{ATP}$ channels,” *American Journal of Physiology*, vol. 273, no. 6 Pt 2, pp. H2687–H2695, 1997.

[95] D. S. Poonnoth, M. A. Nayeeet, S. L. Tilley, C. Ledent, and S. Jamal Mustafa, “CYP-epoxygenases contribute to A2A receptor-mediated aortic relaxation via sarcoclemmal KATP channels,” *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, vol. 303, no. 10, pp. R1003–R1010, 2012.

[96] Y. Cheng, J. F. Ndising, G. Tang, K. Cao, and R. Wang, “Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats,” *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 287, no. 5, pp. H2316–H2323, 2004.

[97] C. L. Heaps and D. K. Bowles, “Gender-specific $K^+$-channel contribution to adenosine-induced relaxation in coronary arterioles,” *Journal of Applied Physiology*, vol. 92, no. 2, pp. 550–558, 2002.

[98] B. K. Kemp and T. M. Cocks, “Adenosine mediates relaxation of human small resistance-like coronary arterioles via $A_2\beta$ receptors,” *British Journal of Pharmacology*, vol. 126, no. 8, pp. 1796–1800, 1999.

[99] Q. Li and D. G. Puro, “Adenosine activates ATP-sensitive $K^+$ currents in pericytes of rat retinal microvessels: Role of $A_2\alpha$ and $A_3$ receptors,” *Brain Research*, vol. 907, no. 1-2, pp. 93–99, 2001.

[100] H. A. Olanrewaju, B. S. Gafurov, and E. M. Lieberman, “Involvement of $K^+$ channels in adenosine A2A and A2B receptor-mediated hyperpolarization of porcine coronary artery endothelial cells,” *Journal of Cardiovascular Pharmacology*, vol. 40, no. 1, pp. 43–49, 2002.

[101] B. C. Sheridan, R. C. McIntyre Jr, D. R. Meldrum, and D. A. Fullerton, “KATP channels contribute to beta- and adenosine receptor-mediated pulmonary vasorelaxation,” *American Journal of Physiology*, vol. 273, no. 5 Pt 2, pp. P926–P933, 1999.

[102] L. Tang, M. Parker, Q. Fei, and R. Loutzhenisher, “Afferent arteriolar adenosine A2A receptors are coupled to KATP in in vitro perfused hydrolephrotic rat kidney,” *American Journal of Physiology*, vol. 278, no. 2 Pt 2, pp. F269–F277, 2000.

[103] D. Ye, W. Zhou, and H.-C. Lee, “Activation of rat mesenteric arterial KATP channels by 11,12-epoxyeicosatrienoic acid,” *American Journal of Physiology - Heart and Circulatory Physiology*, vol. 288, no. 1, pp. H358–H364, 2005.

[104] T. Lu, D. Ye, X. Wang et al., “Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms,” *Journal of Physiology*, vol. 575, no. 2, pp. 627–644, 2006.

[105] D. S. Poonnoth, M. A. Nayeeet, S. S. Kunduri et al., “Role of omega-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice,” *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, vol. 302, no. 4, pp. R400–R408, 2012.

[106] A. Eisenstein and K. Ravid, “G Protein-coupled receptors and adipogenesis: A focus on adenosine receptors,” *Journal of Cellular Physiology*, vol. 229, no. 4, pp. 414–421, 2014.

[107] H. R. Ansari, B. Teng, A. Nadeem et al., “A(1) adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells,” *American Journal of Physiology - Heart and Circulatory Physiology*, vol. 297, no. 3, pp. H1032–H1039, 2009.

[108] “Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group,” *BMJ*, vol. 297, no. 6644, pp. 319–328, 1988.

[109] K. T. Khaw, S. Bingham, A. Welch et al., “Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European prospective investigation into cancer (EPIC-Norfolk),” *The American Journal of Clinical Nutrition*, vol. 80, no. 5, pp. 1397–1403, 2004.

[110] E. L. Lichicn, J. C. McGiff, J. R. Falck, and M. A. Carroll, “Failure to upregulate the adenosine 2A receptor-epoxygenase/arachidonic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats,” *American Journal of Physiology - Renal Physiology*, vol. 295, no. 6, pp. F1696–F1704, 2008.

[111] H. M. Siragy and J. Linden, “Sodium intake markedly alters renal interstitial fluid adenosine,” *Hypertension*, vol. 27, no. 3 Pt 1, pp. 404–407, 1996.

[112] A.-P. Zou, F. Wu, P.-L. Li, and A. W. Cowley Jr., “Effect of chronic salt loading on adenosine metabolism and receptor expression in renal cortex and medulla in rats,” *Hypertension*, vol. 33, no. 1 Pt 2, pp. 511–516, 1999.

[113] H. Andersen, M. G. Jaff, D. Hogh, P. Vanhoutte, and P. B. Hansen, “Adenosine elicits an eNOS-independent reduction in arterial blood pressure in conscious mice that involves adenosine A2A receptors,” *Acta Physiologica*, vol. 203, no. 1, pp. 197–207, 2011.

[114] D. R. Harder, W. B. Campbell, and R. J. Roman, “Role of cytochrome p-450 enzymes and metabolites of arachidonic acid in the control of vascular tone,” *Journal of Vascular Research*, vol. 32, no. 2, pp. 79–92, 1995.

[115] L. Lapuerta, N. Chacos, J. R. Falck, H. Jacobson, and J. H. Capdevila, “Renal microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid,” *American Journal of the Medical Sciences*, vol. 295, no. 4, pp. 275–279, 1988.

[116] K. G. Proctor, J. R. Falck, and J. Capdevila, “Intestinal vasodilation by epoxyeicosatrienoic acids: Arachidonic acid metabolites produced by a cytochrome P450 monooxygenase,” *Circulation Research*, vol. 60, no. 1, pp. 50–59, 1987.

[117] Y. H. Ma, D. R. Harder, J. E. Clark, and R. J. Roman, “Effects of 12-HETE on isolated dog renal arcuate arteries,” *American Journal of Physiology*, vol. 261, no. 2 Pt 2, pp. H451–H456, 1991.

[118] W. B. Campbell, D. Gebremedhin, P. F. Pratt, and D. R. Harder, “Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors,” *Circulation Research*, vol. 78, no. 3, pp. 415–423, 1996.

[119] I. Fleming, “The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolyase axis in the vasculature and cardiovascular disease,” *Pharmacological Reviews*, vol. 66, no. 4, pp. 1106–1140, 2014.

[120] J. Seubert, B. Yang, J. A. Bradbury et al., “Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway,” *Circulation Research*, vol. 95, no. 5, pp. 506–514, 2004.

[121] D. Gebremedhin, Y. H. Ma, J. R. Falck, R. J. Roman, M. VanRollins, and D. R. Harder, “Mechanism of action of cerebral
epoxyeicosatrienoic acids on cerebral arterial smooth muscle,” *American Journal of Physiology*, vol. 263, no. 2 Pt 2, pp. H519–H525, 1992.

[122] J. D. Imig, L. G. Navar, R. J. Roman, K. K. Reddy, and J. R. Falck, “Actions of epoxygenase metabolites on the preglomerular vasculature,” *Journal of the American Society of Nephrology*, vol. 7, no. 11, pp. 2364–2370, 1996.

[123] C. J. Sinal, M. Miyata, M. Tohkin, K. Nagata, J. R. Bend, and F. J. Gonzalez, “Targeted disruption of soluble epoxy hydrolyase reveals a role in blood pressure regulation,” *Journal of Biological Chemistry*, vol. 275, no. 51, pp. 40504–40510, 2000.

[124] A. Hanif, M. L. Edin, D. C. Zeldin, C. Morisseau, and M. A. Nayeem, “Effect of soluble epoxy hydrolyase on the modulation of coronary reactive hyperemia: Role of oxylipins and PPARγ,” *PLoS ONE*, vol. 11, no. 9, article 0162147, 2016.

[125] K. M. Gauthier, C. Deeter, U. M. Krishna et al., “14,15-Epoxeicosa-5(Z)-enoic acid: A selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries,” *Circulation Research*, vol. 90, no. 9, pp. 1028–1036, 2002.

[126] Y. Liu, Y. Zhu, F. Rannou et al., “Laminar flow activates peroxisome proliferator-activated receptor-γ in vascular endothelial cells,” *Circulation*, vol. 110, no. 9, pp. 1128–1133, 2004.

[127] J. D. Coffman and D. E. Gregg, “Reactive hyperemia characteristics of the myocardium,” *The American journal of physiology*, vol. 199, pp. 1143–1149, 1960.

[128] M. P. Kingsbury, M. A. Turner, N. A. Flores, E. Bovill, and D. J. Sheridan, “Endogenous and exogenous coronary vasodilatation are attenuated in cardiac hypertrophy: A morphological defect?” *Journal of Molecular and Cellular Cardiology*, vol. 32, no. 3, pp. 527–538, 2000.

[129] I. Pradhan, C. Ledent, S. J. Mustafa, C. Morisseau, and M. A. Nayeem, “High salt diet modulates vascular response in A(2A)AR(+/-) and A(2A)AR(−/−) mice: role of sEH, PPARγ, and K(ATP) channels,” *Molecular and Cellular Biochemistry*, vol. 404, no. 1-2, pp. 87–96, 2015.

[130] G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall,” *Zeitschrift fur Kardiologie*, vol. 90, 3, pp. 125–132, 2001.

[131] W. A. Hsueh, S. Jackson, and R. E. Law, “Control of vascular cell proliferation and migration by PPAR-γ: A new approach to the macrovascular complications of diabetes,” *Diabetes Care*, vol. 24, no. 2, pp. 392–397, 2001.

[132] S. W. Seto, T. Y. Lam, G. P. H. Leung et al., “Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-γ activation in + db/+ m and + db/+ db mice,” *European Journal of Pharmacology*, vol. 572, no. 1, pp. 40–48, 2007.

[133] M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund, “PPARγ Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice,” *Hypertension*, vol. 43, no. 3, pp. 661–666, 2004.

[134] Z. Cai, G. Zhao, J. Yan et al., “CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice,” *Journal of Lipid Research*, vol. 54, no. 5, pp. 1448–1456, 2013.

[135] L. Ashley Cowart, S. Wei, M.-H. Hsu et al., “The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands,” *Journal of Biological Chemistry*, vol. 277, no. 38, pp. 35105–35112, 2002.

[136] Y. Liu, Y. Zhang, K. Schmelzer et al., “The antiinflammatory effect of laminar flow: The role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 46, pp. 16747–16752, 2005.